Proton therapy for the management of uveal melanoma and other ocular tumors

2016 ◽  
Vol 5 (4) ◽  
pp. 50-50 ◽  
Author(s):  
Kavita K. Mishra ◽  
Inder K. Daftari
Keyword(s):  
Uveal Melanoma ◽  
Proton Therapy

scholarly journals Characterization of the HollandPTC proton therapy beamline dedicated to uveal melanoma treatment and an interinstitutional comparison

2021 ◽  
Author(s):  
Emmanuelle Fleury ◽  
Petra Trnková ◽  
Kees Spruijt ◽  
Joël Herault ◽  
Franciska Lebbink ◽  
...  
Keyword(s):  
Uveal Melanoma ◽  
Proton Therapy ◽  
Melanoma Treatment

Prophylactic Use of Bevacizumab to Avoid Anterior Segment Neovascularization Following Proton Therapy for Uveal Melanoma

2014 ◽  
Vol 158 (4) ◽  
pp. 693-701.e2 ◽  
Author(s):  
Irmela Mantel ◽  
Ann Schalenbourg ◽  
Ciara Bergin ◽  
Aleksandra Petrovic ◽  
Damien C. Weber ◽  
...  
Keyword(s):  
Uveal Melanoma ◽  
Proton Therapy ◽  
Anterior Segment ◽  
Prophylactic Use

Proton beam radiotherapy for uveal melanoma: Results of Curie Institut–Orsay Proton Therapy Center (ICPO)

2006 ◽  
Vol 65 (3) ◽  
pp. 780-787 ◽  
Author(s):  
Rémi Dendale ◽  
Livia Lumbroso-Le Rouic ◽  
Georges Noel ◽  
Loïc Feuvret ◽  
Christine Levy ◽  
...  
Keyword(s):  
Proton Beam ◽  
Uveal Melanoma ◽  
Proton Therapy ◽  
Proton Beam Radiotherapy ◽  
Therapy Center

scholarly journals Quality of life and treatment-related burden during ocular proton therapy: a prospective trial of 131 patients with uveal melanoma

2021 ◽  
Vol 16 (1) ◽  
Author(s):  
Johannes Gollrad ◽  
Christopher Rabsahl ◽  
Aline-Isabel Riechardt ◽  
Jens Heufelder ◽  
Andrea Stroux ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Uveal Melanoma ◽  
Proton Therapy ◽  
Treatment Completion ◽  
Psychological Aspects ◽  
Treatment Procedure ◽  
Short Term ◽  
Short Term Treatment ◽  
Eortc Qlq

Abstract Background Proton beam therapy is a well-established treatment option for patients with uveal melanoma (UM). The treatment procedure, in general, includes placing radiopaque clips to ensure exact eye-positioning during radiotherapy, followed by the delivery of proton irradiation. The short-term burden associated with proton therapy in patients with UM has rarely been addressed. In this prospective study, we investigated the physiological and psychological aspects of proton therapy that might affect the well-being of patients during the different stages of treatment. Methods During the treatment procedure, we conducted longitudinal assessments of the Quality of life (QOL), organ-specific symptoms, and psychological aspects in patients with UM with three questionnaires (EORTC QLQ-C30, EORTC QLQ-OPT30, and GAD-7). Patients completed questionnaires before clip surgery (T0), before proton therapy (T1), after completing treatment (T2), and three months after treatment completion (T3). We also collected data on tumor characteristics and socio-demographics to identify potential risk factors associated with high treatment burdens. Results We prospectively included 131 consecutive patients. Questionnaire data showed a significant, temporary decline in global QOL and an increase in eye-related symptoms, as a result of the clip surgery (T0–T1). After treatment completion (T2), global QOL improved gradually, and none of the eye-related symptoms significantly deteriorated over the course of proton therapy. The global QOL returned to baseline levels three months after treatment (T3). We identified baseline anxiety as an independent risk factor for experiencing an acute treatment-related burden. Furthermore, we found interactions between GAD7 and patient sex showing that anxiety had a more pronounced effect on QOL outcome in female patients. Conclusion The short-term treatment-related burden of ocular proton therapy appeared to be largely associated with the preceding clip surgery, rather than the irradiation procedure. We found that anxiety was strongly associated with experiencing QOL issues during the treatment procedure. Our findings could contribute to the development of future strategies for improving the treatment process and psycho-oncologic patient care.

scholarly journals Monte Carlo calculations and measurements of absorbed dose per monitor unit for the treatment of uveal melanoma with proton therapy

2008 ◽  
Vol 53 (6) ◽  
pp. 1581-1594 ◽  
Author(s):  
Nicholas Koch ◽  
Wayne D Newhauser ◽  
Uwe Titt ◽  
Dan Gombos ◽  
Kevin Coombes ◽  
...  
Keyword(s):  
Monte Carlo ◽  
Uveal Melanoma ◽  
Proton Therapy ◽  
Absorbed Dose ◽  
Monitor Unit ◽  
Monte Carlo Calculations

Scleritis after Proton Therapy in Uveal Melanoma

2012 ◽  
Vol 229 (04) ◽  
pp. 395-398 ◽  
Author(s):  
O. Passarin ◽  
L. Zografos ◽  
A. Schalenbourg ◽  
A. Moulin ◽  
Y. Guex-Crosier
Keyword(s):  
Uveal Melanoma ◽  
Proton Therapy

scholarly journals ROLE OF VITREORETINAL SURGERY IN MAXIMIZING TREATMENT OUTCOME FOLLOWING COMPLICATIONS AFTER PROTON THERAPY FOR UVEAL MELANOMA

Retina ◽  
2013 ◽  
Vol 33 (9) ◽  
pp. 1777-1783 ◽  
Author(s):  
Bao-Khanh Tran ◽  
Ann Schalenbourg ◽  
Etienne Bovey ◽  
Leonidas Zografos ◽  
Thomas J. Wolfensberger
Keyword(s):  
Treatment Outcome ◽  
Uveal Melanoma ◽  
Proton Therapy ◽  
Vitreoretinal Surgery

scholarly journals Clinical Outcomes after International Referral of Uveal Melanoma Patients for Proton Therapy

Cancers ◽  
2021 ◽  
Vol 13 (24) ◽  
pp. 6241
Author(s):  
Marina Marinkovic ◽  
Lennart J. Pors ◽  
Vincent van den Berg ◽  
Femke P. Peters ◽  
Ann Schalenbourg ◽  
...  
Keyword(s):  
Optic Nerve ◽  
Visual Impairment ◽  
Uveal Melanoma ◽  
Proton Therapy ◽  
Distant Metastasis ◽  
Proportional Hazards ◽  
Tumour Size ◽  
Cox Proportional Hazards ◽  
Tumour Control ◽  
Melanoma Patients

Objective: To assess oncological and ophthalmological outcomes after international referral of uveal melanoma patients for proton therapy. Materials and Methods: This is a retrospective study among Dutch uveal melanoma patients who were treated in Switzerland with 60.0 CGE proton therapy (in 4 fractions) from 1987 to 2019. All patients were ineligible for brachytherapy due to tumour size and/or proximity to the optic nerve. Time-to-event analyses were performed using Kaplan–Meier’s methodology and Cox proportional hazards models. Results: There were 103 patients (104 eyes) with a median largest tumour diameter of 19 mm (range 6–26 mm). Tumours were localised centrally (11%), mid-peripherally (65%) or peripherally (34%). Median follow-up was 7 years. Five-year local control, distant metastasis-free survival and eye preservation rates were 94%, 70% and 81% respectively. At five years, severe, moderate and mild visual impairment was observed in respectively 79%, 4% and 6% of the patients. Larger tumour volumes and more central tumour localisation were associated with severe visual impairment. After correction for these factors, dose to the macula, optic disc and retina, but not optic nerve was significantly associated with severe visual impairment. Conclusion: International referral for proton therapy yielded good tumour control and eye preservation rates, but risk of distant metastasis and severe visual impairment were substantial, possibly due to the selection of advanced tumour stages and/or central localisation. Dose to the macula may be more relevant than dose to the optic nerve for preservation of visual acuity, which is relevant for the treatment planning of proton therapy.

PH-0327 Tumour control and visual outcomes after proton therapy for uveal melanoma

2021 ◽  
Vol 161 ◽  
pp. S238-S240
Author(s):  
N. Horeweg ◽  
L.J. Pors ◽  
F.P. Peters ◽  
A. Schalenbourg ◽  
A. Pica ◽  
...  
Keyword(s):  
Uveal Melanoma ◽  
Proton Therapy ◽  
Tumour Control ◽  
Visual Outcomes
Sign in / Sign up

Export Citation Format

Share Document